Pro-apoptotic activity of new analog of anthracyclines - WP 631 in advanced ovarian cancer cell line

Toxicology in Vitro

Volumn 28, Issue 2, 2014, Pages 273-281

  Gajek, Arkadiusz ^a   Denel, Marta ^a   Bukowska, Barbara ^a   Rogalska, Aneta ^a   Marczak, Agnieszka ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Advanced ovarian cancer cells; Apoptosis; Caspases; DNA damage; WP 631

Indexed keywords

3',3' N XYLENYLBIS(DAUNORUBICIN); CALCIUM ION; CASPASE; CYTOCHROME C; DNA; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DNA DEGRADATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALIGNANT ASCITES; OVARY CANCER; PROTEIN CLEAVAGE;

ADVANCED OVARIAN CANCER CELLS; APOPTOSIS; CASPASES; DNA DAMAGE; WP 631;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; CYTOCHROMES C; DAUNORUBICIN; DNA DAMAGE; DOXORUBICIN; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OVARIAN NEOPLASMS; PHOSPHATIDYLSERINES; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES;

EID: 84890191409     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.11.006     Document Type: Article

References (27)

1. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B. Evidence that activation of nuclear Factor-κB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 2004, 67:353-364.
2. Brooks T.A., O'Loughlin K.L., Minderman H., Bundy B.N., Ford L.A., Vredenburg M.R., Bernacki R.J., Priebe W., Baer M.R. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest. New Drugs 2007, 25:115-122.
3. Bruning A., Mylonas I. New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch. Gynecol. Obstet. 2011, 283:1087-1096.
4. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
5. Chaitanya G.V., Steven A.J., Babu P.P. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010, 10.1186/1478-811X-8-31.
6. Cossarizza A., Baccarani-Contri M., Kalashnikova G., Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 1993, 197(1):40-45.
7. Das A., Durrant D., Mitchell C., Mayton E., Hoke N.N., Salloum F.N., Park M.A., Qureshi I., Lee R., Dent P., Kukreja R.C. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc. Natl. Acad. Sci. USA 2010, 107(42):18202-18207.
8. Eisele K., Lang P.A., Kempe D.S., Klarl B.A., Niemöller O., Wieder T., Huber S.M., Duranton C., Lang F. Stimulation of erythrocyte phosphatidylserine exposure by mercury ions. Toxicol. Appl. Pharmacol. 2006, 210(1-2):116-122.
9. Gentry-Maharaj A., Menon U. Screening for ovarian cancer in the general population. Best. Pract. Res. Clin. Obstet. Gynaecol. 2012, 26(2):243-256.
10. Haj H.T.-B., Salerno M., Priebe W., Kozłowski H., Garnier-Suillerot A. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem. Biol. Interact. 2003, 145:349-358.
11. Henry C.M., Hollville E., Martin S.J. Measuring apoptosis by microscopy and flow cytometry. Methods 2013, 10.1016/j.ymeth.2013.01.008.
12. Kagawa S., Gu J., Honda T., McDonnell T.J., Swisher S.G., Roth J.A., Fang B. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin. Cancer Res. 2001, 7(5):1474-1480.
13. Kania K., Matławska-Wasowska K., Osiecka R., Jóźwiak Z. Analysis of aclarubicin-induced cell death in human fibroblasts. Cell Biol. Int. 2007, 31(9):1049-1056.
14. Kluck R.M., McDougall C.A., Harmon B.V., Halliday J.W. Calcium chelators induce apoptosis-evidence that raised intracellular ionised calcium is not essential for apoptosis. Biochim. Biophys. Acta 1994, 1223(2):247-254.
15. Kratz F., Muller I.A., Ryppa C., Warnecke A. Prodrug strategies in anticancer chemotherapy. Chem. Med. Chem. 2008, 3:20-53.
16. Mansilla S., Bataller M., Portugal J. A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells. Biochem. Pharmacol. 2009, 78:123-132.
17. Mansilla S., Portugal J. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. Biochimie 2008, 90:976-987.
18. Mansilla S., Rojas M., Bataller M., Priebe W., Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem. Pharmacol. 2007, 73:934-942.
19. Pozarowski P., Huang X., Gong R.W., Priebe W., Darzynkiewicz Z. Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry A 2004, 57(2):113-119.
20. Rogalska A., Gajek A., Szwed M., Jóźwiak Z., Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol. In Vitro 2011, 25(8):1712-1720.
21. Seo S.B., Hur J.G., Kim M.J., Lee J.W., Kim H.B., Bae J.H., Kim D.W., Kang C.D., Kim S.H. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol. Cancer 2010, 9:199.
22. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
23. Tolomeo M., Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr. Med. Chem. Anticancer Agents 2002, 2(3):387-401.
24. Upadhyay K.K., Bhatt A.N., Mishra A.K., Dwarakanath B.S., Jain S., Schatz C., Le Meins J.F., Farooque A., Chandraiah G., Jain A.K., Misra A., Lecommandoux S. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010, 10:2882-2892.
25. Villamarin S., Ferrer-Miracles N., Mansila S., Priebe W., Portugal J. Induction ofG2/M arrested and inhibition of c-myc and p53 transcription by WP 631 in Jurcat T lymphocytes. Biochem. Phramacol. 2002, 63:1251-1258.
26. Zamorano S., Rojas-Rivera D., Lisbona F., Parra V., Court F.A., Villegas R., Cheng E.H., Korsmeyer S.J., Lavandero S., Hetz C. A BAX/BAK and cyclophilin Dindependent intrinsic apoptosis pathway. PLoS ONE 2012, 7(6):e37782.
27. Zhang G.S., Zhou G.B., Dai C.W. Upregulation and activation of caspase-3 or caspase-8 and elevation of intracellular free calcium mediated apoptosis of indomethacin-induced K562 cells. Chin. Med. J. 2004, 117:978-984.